Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 8 of about 8   

Articles published

DVAX 23.57 +0.33 (1.42%)
price chart
Dynavax Falls After Vaccine Fails to Win Panel Backing
Nov. 16 (Bloomberg) -- Dynavax Technologies Corp. tumbled the most in four years after its hepatitis B vaccine Heplisav failed to win the backing of U.S.
Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine ...
Dynavax's (NASDAQ:DVAX) HEPLISAV had an FDA Advisory Committee on November 15, 2012. The Advisory Committee voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity.
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says
Nov. 13 (Bloomberg) -- Dynavax Technologies Corp.'s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said.
Promising Biotech Stocks With Upcoming FDA Catalysts  Seeking Alpha
This Week in Biotech: Part 2
Dynavax Technologies (NASDAQ:DVAX) joined the disaster du jour column this week after receiving a disappointing safety ruling from the FDA panel for its hepatitis B vaccine, Hepislav.
U.S. Stock Futures Retreat as Obama Holds Budget Talks
Dynavax Technologies Corp. tumbled 47 percent to $2.44 after its hepatitis B vaccine Heplisav failed to win the backing of U.S.
JA Solar Has to Stoop to a Reverse Stock Split
What you are about to read is a sneaky way of announcing a reverse stock split to stay within the listing standards of the $1.00 share price rule.
Dynavax to initiate phase I studies for TLR-9 agonist for asthma
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into phase I clinical studies.
Dendreon: What's The Company Worth Per Share?
The GSK-HGSI bid demonstrates even a company that was struggling the way HSGI was can attract a suitor if the technology product(s) involved are considered a prize. Remember, Human Genome had been troubled by a 69% stock decrease in 2011 (does ...